Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

The identification of calreticulin mutations has thrown light on the genomic landscape of myeloproliferative neoplasms, creating the basis for a molecular classification of these disorders. Additional investigations are now needed to define how somatic mutations, gene expression, demographic data, clinical variables and patient outcome are interconnected. A specific area of research concerning somatic mutations of calreticulin is the potential different biological and clinical effects of type-1 and type-2 mutations.